Imugene's Leslie Chong says they're poised to begin the Australian component of a phase 2 clinical trial of cancer immunotherapy candidate HER-Vaxx following approval from the Human Research Ethics Committee. The approval has been secured following the completion of all necessary pre-clinical safety and efficacy testing of HER-VAXX required to begin the nextHERIZON clinical trial in Australia.
Imugene thrilled with ethics approval for phase 2 HER-Vaxx trial
